These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Chan CS; Guzman JN; Ilijic E; Mercer JN; Rick C; Tkatch T; Meredith GE; Surmeier DJ Nature; 2007 Jun; 447(7148):1081-6. PubMed ID: 17558391 [TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease: return of an old prime suspect. Sulzer D; Schmitz Y Neuron; 2007 Jul; 55(1):8-10. PubMed ID: 17610813 [TBL] [Abstract][Full Text] [Related]
4. What causes the death of dopaminergic neurons in Parkinson's disease? Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA Prog Brain Res; 2010; 183():59-77. PubMed ID: 20696315 [TBL] [Abstract][Full Text] [Related]
6. Potential nondopaminergic drugs for Parkinson's disease. Silverdale MA; Fox SH; Crossman AR; Brotchie JM Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686 [No Abstract] [Full Text] [Related]
7. mtDNA clock runs out for dopaminergic neurons. Manfredi G Nat Genet; 2006 May; 38(5):507-8. PubMed ID: 16642013 [No Abstract] [Full Text] [Related]
8. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
10. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression. Wright AK; Miller C; Williams M; Arbuthnott G Brain Res; 2008 Jun; 1216():78-86. PubMed ID: 18495090 [TBL] [Abstract][Full Text] [Related]
12. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Chan CS; Gertler TS; Surmeier DJ Mov Disord; 2010; 25 Suppl 1():S63-70. PubMed ID: 20187241 [TBL] [Abstract][Full Text] [Related]
18. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease. Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598 [TBL] [Abstract][Full Text] [Related]